NCT06658405View on ClinicalTrials.gov

Clinical Trial Evaluating Secondary HPV Vaccination After Treatment of High-grade Cervical Lesions

PHASE2RecruitingINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

January 13, 2025

Primary Completion Date

October 31, 2028

Study Completion Date

October 31, 2031

Conditions
Cervical Lesion
Interventions
BIOLOGICAL

Human Papillomavirus 9-valent Vaccine, Recombinant

HPV vaccine administered in three doses: first dose on day 1, second dose 2 months later, and third dose 4 months after the second dose, within a one-year period.

Trial Locations (1)

59020

RECRUITING

Centre Oscar Lambret, Lille

All Listed Sponsors
collaborator

Canceropôle Nord Ouest

OTHER

lead

Centre Oscar Lambret

OTHER